Back to Screener

Healthcare

Masimo Corporation(MASI)

Live Price

Offline

$179.95

+0.00% today

1Y Change

+6.98%

Window

Jun 27, 2025 → Jun 12, 2026

Market Cap
$9.35B
Revenue Growth
-27.1%
EPS Growth
+50.5%
Dividend Yield
0.0%

Coverage: 241 bars · Jun 27, 2025 → Jun 12, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Masimo Corporation (MASI) is a Healthcare stock with a market cap of $9.35B and listed on NASDAQ. The stock last traded around $179.95 and up 7.0% across the available one-year price window (Jun 27, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -27.1%, EPS growth of +50.5%, a dividend yield of 0.0%. What stands out right now is revenue -27.1%, EPS +50.5%, free cash flow +36.1% with operating margin 20.3% and ROIC 17.6%. Valuation sits in the middle of the pack at price/sales 6.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MASI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

MASI vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

MASI

—

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

MASI Max Drawdown

-25.64%

Trailing 1Y

SPY Max Drawdown

—

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for MASI and SPY.

Calendar-year return history is still loading or unavailable.

EPS Consensus

2.17

Range 2.16 -> 2.18

No analyst count

vs prior: +10.9%

Revenue Outlook

$0.5B

Range $0.5B -> $0.5B

No analyst count

vs prior: +7.3%

Price Target

--

-- -> --

No analyst count

Recommendations

--

No recommendation feed

No date

Consensus Spread

EPS spread0.8%
Revenue spread0.6%

Lower spread suggests tighter agreement across covering analysts.

Next Earnings

No date

EPS --

Revenue --

No analyst count

EPS Revisions

No revision signal

No recent EPS revision rows

0 revision rows

Trend

EPS trend

Consensus average across visible periods

2.17
Latest visible period
Q4 2027Q1 2029
6 visible pointstrend: +10.9%

Trend

Revenue trend

Average analyst revenue estimate

$0.5B
Latest visible period
Q4 2027Q1 2029
6 visible pointstrend: +7.3%

Timeline

Analyst forecast ladder

Sorted by period end date. Includes both cached rows and live fallbacks from the configured analyst feed.

Q1 2029
Ends Jan 3, 2029
quarter
Revenue
$0.5B
$0.5B to $0.5B
EPS
2.17
2.16 to 2.18
No analyst count
EPS: No analyst count
Apr 28, 02:48 PM UTC
stable/analyst-estimates
Q4 2028
Ends Oct 3, 2028
quarter
Revenue
$0.5B
$0.5B to $0.5B
EPS
1.96
1.95 to 1.97
No analyst count
EPS: No analyst count
Apr 28, 02:48 PM UTC
stable/analyst-estimates
Q3 2028
Ends Jul 3, 2028
quarter
Revenue
$0.5B
$0.5B to $0.5B
EPS
1.94
1.93 to 1.95
No analyst count
EPS: No analyst count
Apr 28, 02:48 PM UTC
stable/analyst-estimates
Q2 2028
Ends Apr 3, 2028
quarter
Revenue
$0.5B
$0.5B to $0.5B
EPS
1.93
1.92 to 1.94
No analyst count
EPS: No analyst count
Apr 28, 02:48 PM UTC
stable/analyst-estimates
Q1 2028
Ends Jan 3, 2028
quarter
Revenue
$0.5B
$0.5B to $0.5B
EPS
1.85
1.84 to 1.85
No analyst count
EPS: No analyst count
Apr 28, 02:48 PM UTC
stable/analyst-estimates
Q4 2027
Ends Oct 3, 2027
quarter
Revenue
$0.4B
$0.4B to $0.4B
EPS
1.64
1.63 to 1.64
No analyst count
EPS: No analyst count
Apr 28, 02:48 PM UTC
stable/analyst-estimates

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.

Read the analyst forecasts guideCompare stocks with this setup